NCT00812396

Biomarkers of Muscle Anabolism (MK-0000-082)

A Randomized, Single-Blind, Placebo-Controlled, Fixed-Sequence, Single-Dose, Parallel Design Study to Utilize Comparative Proteomics to Identify Early Biomarkers of Muscle Anabolism

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: Male
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

This study will evaluate the ability of comparative proteomics to identify early biomarkers of muscle anabolism.

Conditions

• Muscle Anabolism

Interventions

Type	Name	Description
DRUG	Comparator: low dose testosterone	Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
DRUG	Comparator: high dose testosterone	Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
DRUG	Comparator: placebo	Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.

Timeline

• Start date: 2007-11-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2008-12-22
• Last updated: 2015-01-30